Jefferies analyst Matthew Andrews surveyed 50 U.S. physicians and high prescribers of Amarin's Vascepa to assess current use of Vascepa in mixed dyslipidemia and severe high triglycerides, and future prescribing habits based on the REDUCE-IT data. The survey indicates Vascepa is the leading triglycerides-lowering drug in severe hypertriglyceridemia and mixed dyslipidemia, and positive MACE data in the REDUCE-IT trial could increase use 125% and 50%, respectively, Andrews tells investors in a research note. The analyst estimates peak-adjusted U.S. Vascepa sales of $1.06B by 2030. He sees a favorable risk/reward on Amarin shares into the Q3 data. The stock has upside to $7 on positive data and downside to $2.25 on a negative readout, Andrews contends. He keeps a Buy rating on Amarin with a $7 price target.